医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

OPTOLANE Chooses Trustonic to Protect New Connected Medical Diagnostic Devices

2019年12月12日 AM08:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England

Device and application security leader Trustonic today announces that OPTOLANE has selected Trustonic Secured Platform (TSP) to bring security and trust to the company’s new connected medical diagnostic device. The product is primarily used at the point-of-care for early diagnosis and preventative healthcare, particularly for diagnosing cancer, infectious diseases and congenital abnormalities.

Healthcare devices have become top targets for cybercriminals due to their critical nature, the valuable intellectual property they employ and the sensitive personal information that they collect and store. Research shows that there were 8.2 attempted cyberattacks per connected healthcare endpoint in each month of 20181.

To ensure security, privacy and high performance, OPTOLANE’s simple, fast and smart diagnostic platform is based on Nexell’s system on chip (SoC) platform, which integrates Trustonic’s Trusted Execution Environment (TEE)*. OPTOLANE’s in vitro diagnostic (IVD) platform, called LOAA (Lab on an Array) Analyzer, examines blood and tissue samples for multiple targets, including DNA, RNA, proteins and metabolites, in real-time. It was developed to satisfy market demand for ‘sample to answer’ IVD tools and enables sample extraction through to analysis with a single cartridge.

“Investment in connected healthtech is increasing and IVD is an important segment in the global diagnostics industry,” comments Ben Cade, CEO of Trustonic. “These solutions add significant value to diagnosis and treatment, enhancing the well-being of the general public while increasing productivity and reducing costs. But, where personal data this sensitive is being captured, processed, and transmitted, the appropriate steps must be taken to protect it from malicious actors.”

Trustonic’s hardware-backed security platform, TSP, enables secure and private data extraction, processing, storage and transmission. The technology:

  • Enables a secure image processing channel from the sensor to the application processor;
  • Provides cryptographic tools to protect individuals’ sensitive medical data;
  • Ensures data integrity;
  • Creates a secure environment to run algorithms analyzing raw data from the sensor;
  • Encrypts sensitive data when being shared with the cloud.

Do Young Lee, CEO of OPTOLANE, says: “There is clear demand for innovative new diagnostics solutions that go from ‘sample-to-answer’ in real-time. Importantly, though, we fully understand our responsibility to protect patient data. To deliver connectivity while protecting the sensitive personal data collected by diagnostic devices, we needed a proven hardware-backed security foundation. Trustonic’s experience protecting smartphones, wearables and IoT hardware and securing critical mobile applications in the financial and automotive sectors is assurance that our devices and patient data are secured to the highest standard.”

OPTOLANE expects to receive FDA certification for the new device in the first quarter of 2020. Once certification is achieved the product will be available to clinicians in healthcare facilities around the world.

To learn more about Trustonic solutions for connected medical devices, visit: https://www.trustonic.com/solutions/trustonic-secured-platforms-tsp/.

To learn more about OPTOLANE’s product portfolio, visit: http://optolane.com/


1https://healthtechmagazine.net/article/2019/07/why-basic-security-compliance-isnt-enough-healthcare-orgs

View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005664/en/

CONTACT

iseepr

Erin Lovett

trustonic@iseepr.co.uk

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report